Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis

Background and Objective: Myasthenia gravis (MG) is an autoimmune neuromuscular disease. Nearly 10–30% of patients with MG are refractory to conventional therapy. Rituximab (RTX), a monoclonal antibody targeting CD20, is increasingly used in autoimmune disorders. We performed a systematic review and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Cong, Pu, Meng, Chen, Dawei, Shi, Jin, Li, Zhuyi, Guo, Jun, Zhang, Guangyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548630/
https://www.ncbi.nlm.nih.gov/pubmed/34721267
http://dx.doi.org/10.3389/fneur.2021.736190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548630/
https://www.ncbi.nlm.nih.gov/pubmed/34721267
http://dx.doi.org/10.3389/fneur.2021.736190

Ejemplares similares